J. Hedrick

发表

P3.12 Small molecule compounds that correct alternative splicing of the SMN2 gene and restore SMN protein expression and function

S. Peltz, D. Kobayashi, S. Paushkin, 2011, Neuromuscular Disorders.

Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

S. Peltz, A. Jacobson, T. Davis, 2018, Molecular Cancer Therapeutics.

4-Hydroxy-2-pyridones: Discovery and evaluation of a novel class of antibacterial agents targeting DNA synthesis.

J. Narasimhan, A. Branstrom, Josephine Sheedy, 2017, Bioorganic & medicinal chemistry letters.

Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform

Jean Hedrick, S. Peltz, T. Davis, 2016, PloS one.

The nucleoside analog clitocine is a potent and efficacious readthrough agent.

S. Peltz, T. Davis, J. Leszyk, 2017, RNA.

PTC124 targets genetic disorders caused by nonsense mutations

Meenal Patel, Feng He, Masataka Kawana, 2007, Nature.

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential

S. Peltz, Jairo L. Sierra, H. Ren, 2018, PloS one.

Discovery of N-(4'-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication.

Z. Gu, H. Ren, J. Colacino, 2013, Bioorganic & medicinal chemistry letters.

Ribonucleotide reductase, a novel target for gonorrhea

J. Stubbe, J. Narasimhan, A. Branstrom, 2020, bioRxiv.

ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia.

M. Talkowski, S. Slaugenhaupt, P. Dietrich, 2019, American journal of human genetics.